Monopar Therapeutics (MNPR) SEC Filings — 2025

Filings

• Monopar's Cash Soars Post-Offering, Losses Widen Amid Program Shift — 10-Q · Nov 13, 2025
• Monopar Therapeutics Files 8-K — 8-K · Nov 10, 2025
• Monopar Therapeutics Enters Material Definitive Agreement — 8-K · Sep 24, 2025
• Monopar Therapeutics Files 8-K — 8-K · Sep 15, 2025
• Monopar's Q2 Net Loss Narrows to $81,932 Amidst Reverse Stock Split — 10-Q · Aug 12, 2025
• Monopar Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 23, 2025
• Monopar Therapeutics Files Proxy Materials — DEFA14A · May 23, 2025
• Monopar Therapeutics Files 8-K — 8-K · May 13, 2025
• Monopar Therapeutics Files 8-K — 8-K · May 7, 2025
• Monopar Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025
• Monopar Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025
• Monopar Therapeutics Reports Officer/Director Changes & Compensatory Info — 8-K · Mar 3, 2025
• Monopar Therapeutics Relocates Principal Executive Offices — 8-K · Feb 24, 2025